Log In
BCIQ
Print this Print this
 

APO010

  Manage Alerts
Collapse Summary General Information
Company Onxeo S.A.
DescriptionRecombinant fusion protein derived from the pro-apoptotic human Fas ligand (FasL) protein
Molecular Target Fas receptor (CD95)
Mechanism of ActionFas receptor (CD95) agonist
Therapeutic ModalityBiologic: Fusion protein
Latest Stage of DevelopmentPhase I
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation
PartnerOncology Venture ApS

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

11/19/2012

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today